Table 3.
Unadjusted and adjusted ratio of prescribed dose of ESA in HD patients compared to PD patients across gender and races using multivariate Poisson regression models
| Unadjusted | Hemoglobin-adjusted | Case-mix-adjusted | Case-mix- and MICS-adjusted | |
|---|---|---|---|---|
| All patients | 3.5 (3.4–3.6) | 3.4 (3.3–3.6) | 3.6 (3.4–3.7) | 3.6 (3.5–3.7) |
| African-American men | 3.7 (3.5–4.0) | 3.7 (3.5–4.0) | 3.8 (3.6–4.1) | 3.8 (3.5–4.1) |
| African-American women | 3.7 (3.5–4.0) | 3.8 (3.6–4.0) | 4.0 (3.7–4.2) | 4.0 (3.7–4.3) |
| Non-African-American men | 3.3 (3.1–3.6) | 3.3 (3.0–3.5) | 3.3 (3.1–3.6) | 3.4 (3.2–3.6) |
| Non-Africa-American women | 3.4 (3.3–3.6) | 3.4 (3.3–3.5) | 3.6 (3.4–3.7) | 3.7 (3.5–3.9) |
ESA doses are averaged over the entire calendar quarter (13 weeks) per patient. Data are from 10,527 PD patients and 139,103 HD patients between 7/2001 and 6/2006.